Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell carcinoma of the head and neck

Head and Neck

Volumn 37, Issue 11, 2015, Pages 1665-1671

  Yao, Min ^a   Galanopoulos, Nicholas ^a   Lavertu, Pierre ^a   Fu, Pingfu ^b   Gibson, Michael ^a   Argiris, Athanassios ^c   Rezaee, Rod ^a   Zender, Chad ^a   Wasman, Jay ^a   Machtay, Mitchell ^a   Savvides, Panos ^a,d  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HYGEIA HOSPITAL   (Greece)

^d THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

bevacizumab; chemoradiation; docetaxel; head and neck cancer; radiation

Indexed keywords

BEVACIZUMAB; DOCETAXEL; ANTINEOPLASTIC AGENT; TAXOID;

ACUTE CHOLECYSTITIS; ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; BLEEDING; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DEHYDRATION; DERMATITIS; DISTANT METASTASIS FREE SURVIVAL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TREATMENT FAILURE; DYSPHAGIA; ESOPHAGUS STENOSIS; EVALUATION STUDY; FAILURE FREE SURVIVAL; FEMALE; FOLLOW UP; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPERTENSION; INFECTION; INTENSITY MODULATED RADIATION THERAPY; LARYNX INJURY; LEUKOPENIA; LOCAL RECURRENCE FREE SURVIVAL; LYMPHOCYTOPENIA; MALE; MUCOSA INFLAMMATION; OROPHARYNGEAL HEMORRHAGE; OVERALL SURVIVAL; PHARYNGOESOPHAGEAL STENOSIS; PHARYNX DISEASE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION INDUCED MUCOSITIS; RADIATION INJURY; RADIATION NECROSIS; THROMBOSIS; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT REDUCTION; ADJUVANT RADIOTHERAPY; CANCER STAGING; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; HEAD AND NECK NEOPLASMS; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RADIOTHERAPY DOSAGE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR INVASION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 84944072748     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23813     Document Type: Conference Paper

References (25)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Denis F, Garaud P, Bardet E, et al., Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharyngeal carcinoma. J Clin Oncol 2004; 22: 69-76.
3. Adelstein D, Lavertu P, Saxton JP, et al., Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck. Cancer 2000; 88: 876-883.
4. Forastiere AA, Goepfert H, Maor M, et al., Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349: 2091-2098.
5. Pignon JP, Bourhis J, Domenge C, Designé L,. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis on chemotherapy on head and neck cancer. Lancet 2000; 355: 949-955.
6. Pignon JP, le MaîtreA, Maillard E, Bourhis J,; MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92: 4-14.
7. Kies MS, Harris J, Rotman MZ, et al., Phase II randomized trial of postoperative chemoradiation plus cetuximab for high-risk squamous cell carcinoma of the head and neck (RTOG 0234). Am Soc Radiat Oncol 2009; 75: S14-S15.
8. Ferrara N, Davis-Smyth T,. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18: 4-25.
9. Kyzas PA, Cunha IW, Ioannidis JP,. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin Cancer Res 2005; 11: 1434-1440.
10. Presta LG, Chen H, O'Connor SJ, et al., Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57: 4593-4599.
11. Sweeney CJ, Miller KD, Sissons SE, et al., The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001; 61: 3369-3372.
12. Wachsberger P, Burd R, Dicker AP,. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res 2003; 9: 1957-1971.
13. Savvides P, Agarwala SS, Greskovich J, et al., Phase I study of the EGFR tyrosine kinase inhibitor erlotinib in combination with docetaxel and radiation in locally advanced squamous cell cancer of the head and neck (SCCHN). J Clin Oncol 2006; 24(Suppl):Abstract 5545.
14. Savvides P, Yao M, Rezaee R, et al., Phase II study of erlotinib in combination with docetaxel and radiation in locally advanced squamous cell cancer of the head and neck (SCCHN). AHNS 2010 Research Workshop on the Biology, Prevention, and Treatment of Head and Neck Cancer, Arlington, VA. October 28-30, 2010 (oral presentation).
15. Salama JK, Haraf DJ, Stenson KM, et al., A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers. Ann Oncol 2011; 22: 2304-2309.
16. Fury MG, Lee NY, Sherman E, et al., A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer. Cancer 2012; 118: 5008-5014.
17. Hainsworth JD, Spigel DR, Greco FA, et al., Combined modality treatment with chemotherapy, radiation therapy, bevacizumab, and erlotinib in patients with locally advanced squamous carcinoma of the head and neck: a phase II trial of the Sarah Cannon Oncology Research Consortium. Cancer J 2011; 17: 267-272.
18. Yoo DS, Kirkpatrick JP, Craciunescu O, et al., Prospective trial of synchronous bevacizumab, erlotinib, and concurrent chemoradiation in locally advanced head and neck cancer. Clin Cancer Res 2012; 18: 1404-1414.
19. Avastin (Bevacizumab) prescribing information. Available at: http://www.gene.com/download/pdf/avastin-prescribing.pdf. Accessed October 25, 2013.
20. Willett CG, Boucher Y, di Tomaso E, et al., Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10: 145-147.
21. Carmeliet P, Jain RK,. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 2011; 10: 417-427.
22. Ang KK, Pajak T, Wheeler R, et al., A phase III trial to compare standard versus accelerated fractionation in combination with concurrent cisplatin for head and neck carcinomas (RTOG 0129): report of compliance and toxicity. Int J Radiat Oncol Biol Phys 2010; 77: 1-2.
23. Ang KK, Zhang QE, Rosenthal DI, et al., A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). J Clin Oncol 2011; 29(Suppl): abstract 5500.
24. Garden AS, Harris J, Vokes EE, et al., Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase II trial of concurrent radiation and chemotherapy for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 2004; 22: 2856-2864.
25. Johnson DH, Fehrenbacher L, Novotny WF, et al., Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22: 2184-2191.